Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Soft Tissue Sarcoma | Research

A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models

Authors: Ania Naila Guerrieri, Chiara Bellotti, Marianna Penzo, Marta Columbaro, Micaela Pannella, Alessandro De Vita, Marco Gambarotti, Laura Mercatali, Roberta Laranga, Barbara Dozza, Silvia Vanni, Serena Corsini, Tommaso Frisoni, Giacomo Miserocchi, Toni Ibrahim, Enrico Lucarelli

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Myxofibrosarcoma is a rare malignant soft tissue sarcoma characterised by multiple local recurrence and can become of higher grade with each recurrence. Consequently, myxofibrosarcoma represents a burden for patients, a challenge for clinicians, and an interesting disease to study tumour progression. Currently, few myxofibrosarcoma preclinical models are available.

Methods

In this paper, we present a spontaneously immortalised myxofibrosarcoma patient-derived cell line (MF-R 3). We performed phenotypic characterization through multiple biological assays and analyses: proliferation, clonogenic potential, anchorage-independent growth and colony formation, migration, invasion, AgNOR staining, and ultrastructural evaluation.

Results

MF-R 3 cells match morphologic and phenotypic characteristics of the original tumour as 2D cultures, 3D aggregates, and on the chorioallantoic membrane of chick embryos. Overall results show a clear neoplastic potential of this cell line. Finally, we tested MF-R 3 sensitivity to anthracyclines in 2D and 3D conditions finding a good response to these drugs.

Conclusions

In conclusion, we established a novel patient-derived myxofibrosarcoma cell line that, together with the few others available, could serve as an important model for studying the molecular pathogenesis of myxofibrosarcoma and for testing new drugs and therapeutic strategies in diverse experimental settings.
Literature
1.
Fletcher CDM, Bridge J, Hogendoorn P, Mertens F. WHO Classification Tumours. Soft Tissue and Bone Tumours. 5th edition. Lyon (France); 2020.
2.
Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PCW, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006;19:407–16.PubMedCrossRef
3.
Myxofibrosarcoma GM. In: Atlas of Musculoskeletal Tumors and Tumorlike Lesions. Cham: Springer International Publishing; 2014. p. 355–7.
4.
Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.PubMedPubMedCentralCrossRef
5.
Kawashima H, Ogose A, Gu W, Nishio J, Kudo N, Kondo N, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28–35.PubMedCrossRef
6.
Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, et al. Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. Cells. 2018;7:186.PubMedPubMedCentralCrossRef
7.
Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.PubMedPubMedCentralCrossRef
8.
Heitzer E, Sunitsch S, Gilg MM, Lohberger B, Rinner B, Kashofer K, et al. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Mod Pathol. 2017;30:1698–709.PubMedCrossRef
9.
Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.PubMedCrossRef
10.
de Gooyer JM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, Frielink C, Desar IME, de Wilt JHW, et al. Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma. Sci Rep. 2020;10:2915.PubMedPubMedCentralCrossRef
11.
Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-De Bruijn IH, Knijnenburg J, et al. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med. 2009;13:1291–301.PubMedPubMedCentralCrossRef
12.
Lohberger B, Stuendl N, Leithner A, Rinner B, Sauer S, Kashofer K, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep. 2017;7:44700.PubMedPubMedCentralCrossRef
13.
Melone MAB, Valentino A, Margarucci S, Galderisi U, Giordano A, Peluso G. The carnitine system and cancer metabolic plasticity. Cell Death Dis. 2018;9:228.PubMedPubMedCentralCrossRef
14.
Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80–6.PubMedCrossRef
15.
Vanni S, De Vita A, Gurrieri L, Fausti V, Miserocchi G, Spadazzi C, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022;14:175883592210939.CrossRef
16.
Sambri A, Bianchi G, Righi A, Ferrari C, Donati D. Surgical margins do not affect prognosis in high grade myxofibrosarcoma. Eur J Surg Oncol. 2016;42:1042–8.PubMedCrossRef
17.
Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82:361–7.PubMedCrossRef
18.
Kikuta K, Nakayama R, Yoshida A, Sasaki A, Kameyama K, Chuman H, et al. A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma. Jpn J Clin Oncol. 2017;47:334–41.PubMedCrossRef
19.
De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, et al. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. Ther Adv Med Oncol. 2017;9:755–67.PubMedPubMedCentralCrossRef
20.
Salawu A, Fernando M, Hughes D, Reed MWR, Woll P, Greaves C, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058–68.PubMedPubMedCentralCrossRef
21.
Kito F, Oyama R, Sakumoto M, Shiozawa K, Qiao Z, Toki S, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214–22.PubMedCrossRef
22.
Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246–53.PubMedCrossRef
23.
Li D, Zhang T, Gu W, Li P, Cheng X, Tong T, et al. The ALDH1+ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics. Oncol Rep. 2015;33:2291–8.PubMedCrossRef
24.
Deng L, Li D, Gu W, Liu A, Cheng X. Formation of spherical cancer stem-like cell colonies with resistance to chemotherapy drugs in the human malignant fibrous histiocytoma NMFH-1 cell line. Oncol Lett. 2015;10:3323–31.PubMedPubMedCentralCrossRef
25.
Kenan S, Liang H, Goodman HJ, Jacobs AJ, Chan A, Grande DA, et al. 5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study. J Orthop Surg Res. 2020;15:94.PubMedPubMedCentralCrossRef
26.
Huang HYH-Y, Wu W-RWRW-R, Wang YHY-H, Wang JWJ-W, Fang F-MFMF-M, Tsai J-WJWJ-W, et al. ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance. Clin Cancer Res. 2013;19:2861–72.PubMedCrossRef
27.
Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ. Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J. 1986;18:5–14.PubMedCrossRef
28.
29.
Galbiati A, Penzo M, Bacalini MG, Onofrillo C, Guerrieri AN, Garagnani P, et al. Epigenetic up-regulation of ribosome biogenesis and more aggressive phenotype triggered by the lack of the histone demethylase JHDM1B in mammary epithelial cells. Oncotarget. 2017;8:37091–103.PubMedPubMedCentralCrossRef
30.
Kusakawa S, Yasuda S, Kuroda T, Kawamata S, Sato Y. Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation. Sci Rep. 2015;5:17892.PubMedPubMedCentralCrossRef
31.
Derenzini M, Montanaro L, Treré D. What the nucleolus says to a tumour pathologist. Histopathology. 2009;54:753–62.PubMedCrossRef
32.
Derenzini M, Trerè D, Pession A, Montanaro L, Sirri V, Ochs RL. Nucleolar function and size in cancer cells. Am J Pathol. 1998;152:1291–7.PubMedPubMedCentral
33.
34.
Lee C-H, Yu C-C, Wang B-Y, Chang W-W. Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2016;7:1215–26.PubMedCrossRef
35.
Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1266.
36.
37.
Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, et al. Establishment and Characterization of NCC-MFS5-C1: A Novel Patient-Derived Cell Line of Myxofibrosarcoma. Cells. 2022;11:207.PubMedPubMedCentralCrossRef
38.
39.
Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, et al. Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017;15:229.PubMedPubMedCentralCrossRef
40.
Ren L, Mendoza A, Zhu J, Briggs JW, Halsey C, Hong ES, et al. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget. 2015;6:29469–81.PubMedPubMedCentralCrossRef
41.
Fletcher CDMK, Unni FM. The International Agency for Research on Cancer. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: World Health Organization; 2002.
42.
Freedman VH, Shin S il. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. Cell. 1974;3:355–9.PubMedCrossRef
43.
Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA. Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells. J Vis Exp. 2015;2015:52727.
44.
Zhou C, Ji J, Cai Q, Shi M, Chen X, Yu Y, et al. MTA2 enhances colony formation and tumor growth of gastric cancer cells through IL-11. BMC Cancer. 2015;15:343.PubMedPubMedCentralCrossRef
45.
Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer. 1980;25:591–8.PubMedCrossRef
46.
Spinnato P, Sambri A, Fujiwara T, Ceccarelli L, Clinca R, Medellin MR, et al. Myxofibrosarcoma: Clinical and Prognostic Value of MRI Features. Curr Med Imaging Former Curr Med Imaging Rev. 2021;17:217–24.CrossRef
47.
Srivastava A, Srivastava P, Mathur S, Abbas S, Rai N, Tiwari S, et al. Lipid Metabolism and Mitochondria: Cross Talk in Cancer. Curr Drug Targets. 2022;23:606–27.PubMedCrossRef
48.
Willems SM, Schrage YM, Baelde JJ, Briaire-de Bruijn I, Mohseny A, Sciot R, et al. Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology. 2008;52:465–74.PubMedCrossRef
Metadata
Title
A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models
Authors
Ania Naila Guerrieri
Chiara Bellotti
Marianna Penzo
Marta Columbaro
Micaela Pannella
Alessandro De Vita
Marco Gambarotti
Laura Mercatali
Roberta Laranga
Barbara Dozza
Silvia Vanni
Serena Corsini
Tommaso Frisoni
Giacomo Miserocchi
Toni Ibrahim
Enrico Lucarelli
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11658-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China

Research

Effect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis

Research

Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery

Research

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy

Research

Deep learning-based multifeature integration robustly predicts central lymph node metastasis in papillary thyroid cancer

Research

High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits